University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Beth Apsel Winger, MD, PhD

Beth Apsel Winger, MD, PhD

Assistant Professor, Division of Pediatric Hematology/Oncology, UCSF

Cancer Center Program Memberships

Pediatric Malignancies

Education

Yale University, New Haven, CT, BA, 2001, Chemistry
University of California, San Francisco, CA, PhD, 2008, Chemistry & Chemical Biology
University of California, San Francisco, CA, MD, 2011, Medicine
University of California, San Francisco, CA, Residency, 2014, Pediatrics
University of California, San Francisco, CA, Fellowship, 2018, Pediatric Hem/Onc
University of Maryland, Baltimore (Online), 2019, Pharmacometrics

Honors & Awards

  • 1999
    Pfizer Synthetic Organic Chemistry Undergraduate Summer Research Fellowship
  • 2000
    Richter Summer Fellowship, Yale University
  • 2001
    Honors in Chemistry, Magna Cum Laude, Yale University
  • 2001 - 2002
    Fulbright Graduate Student Award, Fulbright Association
  • 2007 - 2008
    University of California Cancer Research Coordinating Committee Fellowship, University of California
  • 2015
    Molecular Biology in Clinical Oncology Workshop, American Association of Cancer Research
  • 2017 - 2020
    St. Baldrick's Foundation Fellowship Award, St. Baldrick's Foundation
  • 2017 - 2020
    Frank A. Campini Foundation Award, Frank A. Campini Foundation
  • 2020 - 2021
    Mary Anne Koda-Kimble Award for Innovation, UCSF
  • 2020 - 2021
    Resource Allocation Program Grant (co-PI), UCSF
  • 2020 - 2021
    Helen Diller Family Comprehensive Cancer Center Junior Clinical Investigator Award, UCSF

Selected Publications

  1. Shukla P, Goswami S, Keizer RJ, Winger BA, Kharbanda S, Dvorak CC, Long-Boyle J. Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population. Front Pharmacol. 2020; 11:888.
    View on PubMed
  2. Wang H, Long-Boyle J, Winger BA, Nicolaides T, Mueller S, Prados M, Ivaturi V. Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas. J Clin Pharmacol. 2020 May 31.
    View on PubMed
  3. Apsel Winger B, Cortopassi WA, Garrido Ruiz D, Ding L, Jang K, Leyte-Vidal A, Zhang N, Esteve-Puig R, Jacobson MP, Shah NP. ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT. Cancer Res. 2019 08 15; 79(16):4283-4292.
    View on PubMed
  4. Winger BA, Foy E, Sud SR, MacKenzie JD, Pua HH, Lau AH, Heyman MB, Laszik Z, Tureen J. Mycobacterium bovis Enterocolitis in an Immunocompromised Host. J Pediatr Gastroenterol Nutr. 2016 07; 63(1):e17-9.
    View on PubMed
  5. Apsel Winger B, Shah NP. PPAR?: Welcoming the New Kid on the CML Stem Cell Block. Cancer Cell. 2015 Oct 12; 28(4):409-411.
    View on PubMed
  6. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009 Feb 10; 7(2):e38.
    View on PubMed
  7. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov; 4(11):691-9.
    View on PubMed
  8. Zunder ER, Knight ZA, Houseman BT, Apsel B, Shokat KM. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell. 2008 Aug 12; 14(2):180-92.
    View on PubMed
  9. Mackey ZB, Baca AM, Mallari JP, Apsel B, Shelat A, Hansell EJ, Chiang PK, Wolff B, Guy KR, Williams J, McKerrow JH. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem Biol Drug Des. 2006 May; 67(5):355-63.
    View on PubMed
  10. Pillinger MH, Dinsell V, Apsel B, Tolani SN, Marjanovic N, Chan ES, Gomez P, Clancy R, Chang LF, Abramson SB. Regulation of metalloproteinases and NF-kappaB activation in rabbit synovial fibroblasts via E prostaglandins and Erk: contrasting effects of nabumetone and 6MNA. Br J Pharmacol. 2004 Jul; 142(6):973-82.
    View on PubMed
  11. Pillinger MH, Rosenthal PB, Tolani SN, Apsel B, Dinsell V, Greenberg J, Chan ES, Gomez PF, Abramson SB. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation. J Immunol. 2003 Dec 01; 171(11):6080-9.
    View on PubMed

Go to UCSF Profiles, powered by CTSI